"Designing Growth Strategies is in our DNA"

Bronchopulmonary Dysplasia– Pipeline Review, 2019

Region : | Published Date: Upcoming | Report ID: FBI100981| Status : Pipeline



Bronchopulmonary dysplasia (BPD) is a type of chronic lung disease that affects premature infants who have respiratory distress syndrome and have low birth weight (LBW) shortly after birth. In 2018, according to the report published by National Jewish Health, it was estimated that 40% of new-born babies developed bronchopulmonary dysplasia every year. Wheezing, bluish discoloration of the skin around nails and lips due to lack of oxygen in the blood, reoccurring lung infections and rapid breathing are some of the symptoms shown by infants having bronchopulmonary dysplasia

Bronchopulmonary dysplasia can be diagnosed using chest X-rays or through the usage of pulse oximetry in infants who need continuous oxygen supply due to severe respiratory issues. Other diagnostic measures also include continuous heart monitoring to check any complications of pulmonary hypertension associated with bronchopulmonary dysplasia. Medications such as diuretic medicines which includes furosemide, chlorothiazide, and spironolactone that help in the removal of excess fluid from the infant’s body; anti-inflammatory drugs like montelukast and inhaled corticosteroids such as budesonide and fluticasone, additionally, the usage of ventilators support is some of the options available for the treatment of bronchopulmonary dysplasia in premature infants.

Pharmaceutical companies, along with government-funded organizations, have been focusing on studying and developing new treatment options for bronchopulmonary dysplasia. For instance; PNEUMOSTEM, which is being studied by MEDIPOST Co., Ltd., is currently in phase-2 clinical trials for the study of the efficacy and safety of PNEUMOSTEM for the prevention and treatment of severe bronchopulmonary dysplasia (severe BPD) in premature infants

To get details on market share, speak to our analyst

At present, around 70% of the pipeline candidates for Bronchopulmonary Dysplasia are in the phase-1 and phase- stage. Government-funded organizations sponsor more than half of the studies.

Report Description

The report on ‘Bronchopulmonary Dysplasia– Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bronchopulmonary Dysplasia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bronchopulmonary Dysplasia.

The report on ‘Bronchopulmonary Dysplasia– Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

  • A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
  • Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
  • Overview of dormant and discontinued pipeline products
  • Key insights about the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
  • Overview of the latest developments; news articles, press release, and relevant conferences

Report Methodology

  • All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
  • Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

  • Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Bronchopulmonary Dysplasia
  • Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
  • Identify the focus of leading players investing in the research activities for Bronchopulmonary Dysplasia
  • Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
  • Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary


  • 2050

Healthcare Clients

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.